Liver Damage Patient Deaths Lead FDA to Halt SeaGen Leukemia Trials
December 28, 2016 | Seattle Genetics' work to develop a drug to treat a form of leukemia has hit a roadblock following the deaths of four patients in clinical trials. The FDA placed a clinical hold or partial holds on three early-stage trials evaluating the company's drug. Xconomy